Search
Diabetes News
Home

Work Type, Duration May Influence Diabetes Risk

Posted by dlife on Mon, Sep 29, 14, 09:52 AM 0 Comment

September 26, 2014 (HealthDay) - Working long hours may increase your risk for diabetes, a new study suggests. But the finding seems to depend on your job.

Researchers examined data from prior studies involving more than 222,000 men and women in the United States, Europe, Japan and Australia who were followed for an average of 7.6 years.

The initial analysis revealed no difference in the risk of type 2 diabetes among people who w

Continue reading "Work Type, Duration May Influence Diabetes Risk"

Email this

Treatment Combo Boosts A1C Control in Type 2 Diabetes

Posted by dlife on Tue, Sep 23, 14, 04:35 PM 0 Comment

September 23, 2014 (Healio) - Whether already on metformin or drug-naive, patients with type 2 diabetes achieved better HbA1c control with fixed-dose combinations of empagliflozin/linagliptin than either therapy alone, according to research presented at the 50th European Association for the Study of Diabetes Annual Meeting.

The fixed-dose combinations were well tole

Continue reading "Treatment Combo Boosts A1C Control in Type 2 Diabetes"

Email this

Roche's Glucose Monitor with Insulin Calculator Wins FDA Nod

Posted by dlife on Tue, Sep 23, 14, 04:28 PM 0 Comment

September 23, 2014 (MassDevice) - Biotech titan Roche secured a landmark FDA win with clearance for its Accu-Chek Aviva Expert blood glucose meter, the 1st of its kind with a built-in insulin calculator to help guide patient therapy.

A significant portion of the 6 million estimated diabetics in the U.S. use multiple daily injections of insulin to manage their disease. These patients must obtain regular blood glucose readings and perform sometimes complex calculations to determin

Continue reading "Roche's Glucose Monitor with Insulin Calculator Wins FDA Nod"

Email this

Omarigliptin, Sitagliptin Show Comparable Diabetes Outcomes

Posted by dlife on Tue, Sep 23, 14, 04:30 PM 0 Comment

September 23, 2014 (Healio) - Similar efficacy and safety was found between once-weekly omarigliptin and once-daily sitagliptin among patients with type 2 diabetes, according to a presenter at the 50th European Association for the Study of Diabetes Annual Meeting.

"Omarigliptin is a potent, highly selective oral DPP-IV inhibitor," Ira Gantz, MD, a clinical researcher for metabolism at Merck Resea

Continue reading "Omarigliptin, Sitagliptin Show Comparable Diabetes Outcomes"

Email this

Diabetic Peripheral Neuropathy Increased Risk for Fall

Posted by dlife on Mon, Sep 22, 14, 11:39 AM 0 Comment

September 22, 2014 (Healio) - Recent data presented at the 50th European Association for the Study of Diabetes Annual Meeting suggest that patients with diabetic peripheral neuropathy are more likely to sway during stair climbing, putting them at a greater risk for falls.

Steven Brown, a PhD student at Manchester Metropolitan University in the United Kingdom, and colleagues evaluated 22 patien

Continue reading "Diabetic Peripheral Neuropathy Increased Risk for Fall"

Email this

Sign up for FREE dLife Newsletters

dLife Membership is FREE! Get exclusive access, free recipes, newsletters, savings, and much more! FPO

Congratulations!
You are subscribed!
Congratulations!
You are subscribed!
Congratulations!
You are subscribed!
Sponsor Specials

dLife Weekly Poll

On a scale of one to five, how much has diabetes affected your concentration?